Effect of Intermittent Administration of a Combination of Amodiaquin and Primaquine (Camoprim®) on the Hematocrit of Primaquine-Sensitive and Non-Sensitive Children

View More View Less
  • Department of Clinical Investigation, Parke, Davis & Company, Ann Arbor, Michigan


A combination of amodiaquin-primaquine in tablet form was administered in weekly doses, containing 0.3 to 0.5 mg of primaquine, to 11 primaquine-sensitive children, 92 non-sensitive children and 235 African children.

The fall in the mean and individual hematocrit in primaquine-sensitive children without anemia on intermittent, weekly medication with doses containing 0.29 and 0.45 mg of primaquine per pound of body weight was less than that shown on 7 days of continuous daily dosage of 0.29 mg per pound, despite the fact that daily administration was employed when many of the mature red cells had presumably been destroyed by the previous intermittent, weekly regimen. The fall in the hematocrit at the 0.45 mg per pound weekly dosage level occurred earlier and was more marked than at 0.29 mg. The fall in the mean hematocrit at the 0.45 mg dosage was greatest on the 12th day after the first dose, reaching 4.2%. It is felt that this degree of hemolysis is not sufficient to be dangerous except where severe renal insufficiency is present.

In 235 African children given weekly doses containing between 0.3 and 0.5 mg of primaquine per pound of body weight, no hemolysis was demonstrable by weekly hemoglobin estimations. The average hemoglobin reading for the 235 children rose and remained above the initial level during all 5 weeks of the study.

The combination of amodiaquin and primaquine was well tolerated and readily accepted by the children.